KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Goodwill & Intangibles (2018 - 2025)

Twist Bioscience (TWST) has disclosed Goodwill & Intangibles for 5 consecutive years, with $145.5 million as the latest value for Q3 2022.

  • On a quarterly basis, Goodwill & Intangibles rose 246.02% to $145.5 million in Q3 2022 year-over-year; TTM through Sep 2022 was $145.5 million, a 246.02% increase, with the full-year FY2022 number at $145.5 million, up 246.02% from a year prior.
  • Goodwill & Intangibles was $145.5 million for Q3 2022 at Twist Bioscience, up from $62.5 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $145.5 million in Q3 2022 to a low of $458000.0 in Q4 2019.
  • A 5-year average of $22.9 million and a median of $1.5 million in 2019 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: crashed 59.75% in 2019, then skyrocketed 7302.81% in 2021.
  • Twist Bioscience's Goodwill & Intangibles stood at $1.1 million in 2018, then plummeted by 59.75% to $458000.0 in 2019, then skyrocketed by 148.47% to $1.1 million in 2020, then surged by 7302.81% to $84.2 million in 2021, then skyrocketed by 72.77% to $145.5 million in 2022.
  • Per Business Quant, the three most recent readings for TWST's Goodwill & Intangibles are $145.5 million (Q3 2022), $62.5 million (Q1 2022), and $84.2 million (Q4 2021).